135 results
8-K
EX-99.1
AVXL
Anavex Life Sciences Corporation
9 May 24
Anavex Life Sciences Reports Fiscal 2024 Second Quarter Financial Results and Provides Business Update
8:00am
that ANAVEX®3-71,
which targets SIGMAR1 and M1 muscarinic receptors, is a promising clinical stage drug candidate demonstrating disease-modifying
8-K
EX-99.1
xni k8y5k
2 Dec 22
Other Events
8:13am
8-K
EX-99.1
nws p0i9f
4 Mar 22
Anavex Life Sciences Announces Change of Auditor to Grant Thornton LLP
7:00am
8-K
EX-99.1
o8gl6tqmx
4 Feb 22
Other Events
7:38am
8-K
EX-99.1
eqbcb0dfox
27 Sep 21
Other Events
8:10am
S-3ASR
8rc d4rpz9db
24 Sep 21
Automatic shelf registration
5:04pm
8-K
EX-99.1
r2t7egl372f05en0
24 Jun 21
Anavex Life Sciences Announces $50 Million Registered Direct Offering
4:21pm
424B5
xp3zdzuis6wc r8028
24 Jun 21
Prospectus supplement for primary offering
8:46am